XBI ETF holdings (NYSE) - Page 4 | MetaTrader

Abrir gráfico completo Full chart

Visão geral Todos os ativos Mapa de calor

Principais ativos Market Value Shares Weight %

QURE uniQure NV 65.4 M 2.7 M 0.8%

APGE Apogee Therapeutics Inc 60.8 M 805.5 K 0.8%

VCYT Veracyte Inc 60.2 M 1.4 M 0.8%

RARE Ultragenyx Pharmaceutical Inc 60.2 M 2.6 M 0.8%

TWST Twist Bioscience Corp 60.1 M 1.9 M 0.8%

CPRX Catalyst Pharmaceuticals Inc 60.0 M 2.6 M 0.8%

SNDX Syndax Pharmaceuticals Inc 56.4 M 2.7 M 0.7%

IMVT Immunovant Inc 55.7 M 2.2 M 0.7%

DNLI Denali Therapeutics Inc 52.4 M 3.2 M 0.7%

VRDN Viridian Therapeutics Inc 51.4 M 1.7 M 0.7%

CLDX Celldex Therapeutics Inc 51.4 M 1.9 M 0.7%

BCRX BioCryst Pharmaceuticals Inc 49.4 M 6.3 M 0.6%

AGIO Agios Pharmaceuticals Inc 48.5 M 1.8 M 0.6%

IRON Disc Medicine Inc 47.5 M 598.0 K 0.6%

STOK Stoke Therapeutics Inc 47.4 M 1.5 M 0.6%

Dynavax Technologies Corp 46.9 M 3.0 M 0.6%

VCEL Vericel Corp 45.1 M 1.3 M 0.6%

MNKD MannKind Corp 42.5 M 7.5 M 0.5%

IMNM Immunome Inc 40.4 M 1.9 M 0.5%

JANX Janux Therapeutics Inc 40.1 M 2.9 M 0.5%

1
2
3
4
5
6
7
8

Notícias

First Quarter Earnings: Sharpening Sector Divergence

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

3 Reasons To Stick With Growth Stocks In Rotating Markets

Seeking Innovation Beyond Tech? Insight On Healthcare Stocks

Biotech Investors Are Tuning Out the MAHA Chaos

Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Preço-alvo da Capricor mantido em US$ 63 pela B.Riley com avanços na FDA

FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint

Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)

Juros a descoberto da Intellia lideram alta entre biotechs, diz Baird

Mizuho reduz preço-alvo da Immunocore para US$ 34 após revisão de receita